Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

1. Cannabis

Cannabis This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. 1 Received: October 10, 2018; Accepted: October 17, 2018 Original Article Canadian Association (...) of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders Christopher N. Andrews MD, MSc 1 , Shane M. Devlin MD 1 , Bernard Le Foll MD, PhD 2,3,4,5 , Benedikt Fischer PhD 6 , Frances Tse MD, MPH 7 , Martin Storr MD 8 , Stephen E. Congly MD, MSc 1 1 Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 2 T ranslational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre

Publication 48906132018

2. Cannabis for the treatment of ulcerative colitis.

Cannabis for the treatment of ulcerative colitis. BACKGROUND: Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown. OBJECTIVES: To assess the efficacy and safety of cannabis and cannabinoids for the treatment of patients (...) with UC. SEARCH METHODS: We searched MEDLINE, Embase, WHO ICTRP, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov and the European Clinical Trials Register from inception to 2 January 2018. Conference abstracts and references were searched to identify additional studies. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing any form or dose of cannabis or its cannabinoid derivatives (natural or synthetic) to placebo or an active therapy for adults

Cochrane2018

3. Cannabis for the treatment of Crohn's disease.

Cannabis for the treatment of Crohn's disease. BACKGROUND: Crohn's disease (CD) is a chronic immune-mediated condition of transmural inflammation in the gastrointestinal tract, associated with significant morbidity and decreased quality of life. The endocannabinoid system provides a potential therapeutic target for cannabis and cannabinoids and animal models have shown benefit in decreasing inflammation. However, there is also evidence to suggest transient adverse events such as weakness (...) , dizziness and diarrhea, and an increased risk of surgery in people with CD who use cannabis. OBJECTIVES: The objectives were to assess the efficacy and safety of cannabis and cannabinoids for induction and maintenance of remission in people with CD. SEARCH METHODS: We searched MEDLINE, Embase, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov, and the European Clinical Trials Register up to 17 October 2018. We searched conference abstracts, references and we also

Cochrane2018

4. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Dissemination Centre Discover Portal NIHR DC Discover Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol (...) and require an alternative. There has been widespread interest from the public and the media in the medical use of cannabis and its active components (called cannabinoids). Some countries such as the Netherlands have legalised their use for medical purposes. Laboratory and animal studies have suggested that cannabinoids might reduce epileptic seizures, and they have shown promise in some studies in people with severe epilepsy. However, there has been concern about the quality of these studies

NIHR Dissemination Centre2018

5. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies

Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies 29847469 2018 09 21 1872-6623 159 10 2018 Oct Pain Pain Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. 1932-1954 10.1097/j.pain.0000000000001293 This review examines evidence for the effectiveness (...) of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials.gov were searched in July 2017. Analyses were conducted using Revman 5.3 and Stata 15.0. A total of 91 publications containing 104 studies were eligible (n = 9958 participants), including 47 randomised controlled

EvidenceUpdates2018

8. Cannabis

Cannabis Top results for cannabis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for cannabis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

10. Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis

Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis Article Text Causes and risk factors Daily use of high-potency cannabis is associated

Evidence-Based Mental Health2018

11. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence 29511052 2018 03 07 1468-330X 2018 Mar 06 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. jnnp-2017-317168 10.1136/jnnp-2017-317168 Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic (...) as adjuvant treatment in paediatric-onset drug-resistant epilepsy may reduce seizure frequency. Existing RCT evidence is mostly in paediatric samples with rare and severe epilepsy syndromes; RCTs examining other syndromes and cannabinoids are needed. CRD42017055412. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Stockings Emily E National Drug and Alcohol Research

EvidenceUpdates2018

12. Cannabis-based medicines for chronic neuropathic pain in adults.

Cannabis-based medicines for chronic neuropathic pain in adults. BACKGROUND: This review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological treatment options for neuropathic pain afford substantial benefit for only a few people, often with adverse effects that outweigh the benefits. There is a need to explore other treatment options (...) , with different mechanisms of action for treatment of conditions with chronic neuropathic pain. Cannabis has been used for millennia to reduce pain. Herbal cannabis is currently strongly promoted by some patients and their advocates to treat any type of chronic pain. OBJECTIVES: To assess the efficacy, tolerability, and safety of cannabis-based medicines (herbal, plant-derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults. SEARCH METHODS

Cochrane2018

14. Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines

Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines Published on: December 21, 2017 Project Number: RA0944-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What (...) is the clinical effectiveness on the use of medical cannabis in the elderly? What are the evidence-based guidelines on the use of medical cannabis in the elderly? Key Message One systematic review, four randomized controlled trials, and two non-randomized studies were identified regarding the clinical effectiveness on the use of medical cannabis in the elderly. Tags geriatrics, aged, cannabinoids, cannabis, marijuana abuse, older adult, Elderly Files Rapid Response Reference List Published : December 21, 2017

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

15. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 28934780 2017 09 21 2017 09 21 2150-1149 20 6 2017 Sep Pain physician Pain Physician Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. E755-E796 The management of chronic pain is a complex challenge worldwide. Cannabis-based medicines (CBMs) have proven to be efficient in reducing chronic (...) studies were extremely heterogeneous. Only 7 studies reported on the patients' history of prior consumption of CBMs. Furthermore, since cannabinoids are surrounded by considerable controversy in the media and society, cannabinoids have marked effects, so that inadequate blinding of the placebo could constitute an important source of limitation in these types of studies. The current systematic review suggests that CBMs might be effective for chronic pain treatment, based on limited evidence, primarily

EvidenceUpdates2017

17. Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines

Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Integrated Cessation Programs for Adults Who Smoke Cannabis and Tobacco: Clinical Effectiveness and Guidelines Published (...) on: September 28, 2017 Project Number: RA0934-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of integrated cessation programs in adults who smoke cannabis and tobacco? What are the evidence-based guidelines associated with the use of integrated cessation programs in adults who smoke cannabis and tobacco? Key Message One systematic review with meta-analysis and one randomized controlled trial were identified

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

18. Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines

Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Pharmacological Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness (...) and Guidelines Published on: September 22, 2017 Project Number: RA0933-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of pharmacological interventions for the prevention or treatment of cannabis use in adults? What are the evidence-based guidelines associated with the use of pharmacological interventions for the prevention or treatment of cannabis use in adults? Key Message Four systematic reviews and two randomized controlled

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

19. Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines

Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Psychological and Psychosocial Interventions for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Psychological and Psychosocial Interventions (...) for the Prevention or Treatment of Cannabis Use: Clinical Effectiveness and Guidelines Published on: September 15, 2017 Project Number: RA0932-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of psychological and psychosocial interventions for the prevention or treatment of cannabis use in adults? What are the evidence-based guidelines associated with the use of psychological and psychosocial interventions

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017